Abstract
Systemic lupus erythematosus (SLE) is a chronic, relapsing–remitting, multisystemic autoimmune inflammatory disorder that predominantly affects women of childbearing age. Much has been written about the clinical course and long-term damage associated with SLE, as well as the reduced life expectancy of patients with this condition. In addition, studies have emphasized the socioeconomic and psychosocial impact of SLE, although the monetary cost of caring for patients with the disorder has only been evaluated in a modest number of studies and a restricted number of countries. SLE has a negative impact on quality of life and is associated with high health-care costs and significant productivity loss. Factors associated with increased cost of SLE include long disease duration, high disease activity and damage, poor physical and mental health, and high education and employment levels. Similarly, high disease activity and damage, poor physical health, certain disease manifestations, as well as poor family and social support are associated with poor health-related quality of life outcomes. SLE incurs a great burden on both the patient and society. Long-term prospective studies should be encouraged to monitor the costs and psychosocial impact of this condition, and to better understand the factors that are associated with poor outcomes.
Key Points
-
Systemic lupus erythematosus (SLE) has a significant negative impact on a patient's quality of life, and is associated with high health-care costs and loss of productivity
-
Increased disease activity and damage, poor physical health, and poor family and social support are associated with a reduced quality of life in patients with SLE
-
Patients with certain manifestations of SLE, such as disfiguring cutaneous disease, have a worse quality of life than patients without these manifestations
-
Health-care costs are higher in patients with a long disease duration, high SLE disease activity and damage, poor physical and mental health, and high education and employment level
-
Long-term prospective studies are needed to evaluate the costs of SLE and to assist policymakers in the future elaboration of health-care resource planning and allocation
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Petri, M. Epidemiology of systemic lupus erythematosus. Best Pract. Res. Clin. Rheumatol. 16, 847–858 (2002).
Tikly, M. & Navarra, S. V. Lupus in the developing world—is it any different? Best Pract. Res. Clin. Rheumatol. 22, 643–655 (2008).
Trager, J. & Ward, M. M. Mortality and causes of death in systemic lupus erythematosus. Curr. Opin. Rheumatol. 13, 345–351 (2001).
Rahman, P., Gladman, D. D., Urowitz, M. B., Hallett, D. & Tam, L. S. Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus. Lupus 10, 93–96 (2001).
Mok, C. C., Mak, A., Chu, W. P., To, C. H. & Wong, S. N. Long-term survival of southern Chinese patients with systemic lupus erythematosus: a prospective study of all age-groups. Medicine (Baltimore) 84, 218–224 (2005).
Manzi, S. et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am. J. Epidemiol. 145, 408–415 (1997).
Björnådal, L., Yin, L., Granath, F., Klareskog, L. & Ekbom, A. Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population-based study 1964–95. J. Rheumatol. 31, 713–719 (2004).
Nossent, J. et al. Current causes of death in systemic lupus erythematosus in Europe, 2000–2004: relation to disease activity and damage accrual. Lupus 16, 309–317 (2007).
Urowitz, M. B., Gladman, D. D., Tom, B. D., Ibañez, D. & Farewell, V. T. Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus. J. Rheumatol. 35, 2152–2158 (2008).
Cardoso, C. R., Signorelli, F. V., Papi, J. A. & Salles, G. F. Initial and accrued damage as predictors of mortality in Brazilian patients with systemic lupus erythematosus: a cohort study. Lupus 17, 1042–1048 (2008).
Danila, M. I. et al. Renal damage is the most important predictor of mortality within the damage index: data from the LUMINA LXIV, a multiethnic US cohort. Rheumatology (Oxford) 48, 542–545 (2009).
Mok, C. C., To, C. H. & Mak, A. Neuropsychiatric damage in Southern Chinese patients with systemic lupus erythematosus. Medicine (Baltimore) 85, 221–228 (2006).
Ramsey-Goldman, R. Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data. Arthritis Rheum. 42, 882–890 (1999).
Bultink, I. E., Lems, W. F., Kostense, P. J., Dijkmans, B. A. & Voskuyl, A. E. Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. Arthritis Rheum. 52, 2044–2050 (2005).
Yee, C. S. et al. Prevalence and predictors of fragility fractures in systemic lupus erythematosus. Ann. Rheum. Dis. 64, 111–113 (2005).
Mak, A., Mok, C. C. & To, C. H. Incidence and risk factors of fragility fractures in southern Chinese patients with systemic lupus erythematosus. Ann. Rheum. Dis. 65 (Suppl.), S423 (2006).
Lau C. S., Yin, G. & Mok, M. Y. Ethnic and geographical differences in systemic lupus erythematosus: an overview. Lupus 15, 715–719 (2006).
Clarke, A. E. et al. Underestimating the value of women: assessing the indirect costs of women with systemic lupus erythematosus. Tri-Nation Study Group. J. Rheumatol. 27, 2597–2604 (2000).
Utset, T. O., Fink, J. & Doninger, N. A. Prevalence of neurocognitive dysfunction and other clinical manifestations in disabled patients with systemic lupus erythematosus. J. Rheumatol. 33, 531–538 (2006).
Bertoli, A. M., Fernández, M., Alarcón, G. S., Vilá, L. M. & Reveille, J. D. Systemic lupus erythematosus in a multiethnic US cohort LUMINA (XLI): factors predictive of self-reported work disability. Ann. Rheum. Dis. 66, 12–17 (2007).
Mok, C. C., Cheung, M. Y., Ho, L. Y., Yu, K. L. & To, C. H. Risk and predictors of work disability in Chinese patients with systemic lupus erythematosus. Lupus 17, 1103–1107 (2008).
Tam, L. S. et al. The relationship between neuropsychiatric, clinical, and laboratory variables and quality of life of Chinese patients with systemic lupus erythematosus. J. Rheumatol. 35, 1038–1045 (2008).
Clarke, A. E. et al. An international perspective on the well being and health care costs for patients with systemic lupus erythematosus. Tri-Nation Study Group. J. Rheumatol. 26, 1500–1511 (1999).
Clarke, A. E. et al. The systemic lupus erythematosus Tri-Nation Study: absence of a link between health resource use and health outcome. Rheumatology (Oxford) 43, 1016–1024 (2004).
Clarke, A. E. et al. A Canadian study of the total medical costs for patients with systemic lupus erythematosus and the predictors of costs. Arthritis Rheum. 36, 1548–1559 (1993).
Sutcliffe, N., Clarke, A. E., Taylor, R., Frost, C. & Isenberg, D. A. Total costs and predictors of costs in patients with systemic lupus erythematosus. Rheumatology (Oxford) 40, 37–47 (2001).
Huscher, D. et al. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann. Rheum. Dis. 65, 1175–1183 (2006).
Panopalis, P. et al. Health care costs and costs associated with changes in work productivity among persons with systemic lupus erythematosus. Arthritis Rheum. 59, 1788–1795 (2008).
Clarke, A. E. et al. SLE patients with renal damage incur higher health care costs. Rheumatology (Oxford) 47, 329–333 (2008).
Panopalis, P. et al. The systemic lupus erythematosus Tri-Nation Study: cumulative indirect costs. Arthritis Rheum. 57, 64–70 (2007).
Hanly, J. G. Disease activity, cumulative damage and quality of life in systemic lupus erythematosus: results of a cross sectional study. Lupus 6, 243–247 (1997).
Abu-Shakra, M. et al. Quality of life in systemic lupus erythematosus: a controlled study. J. Rheumatol. 26, 306–309 (1999).
Thumboo, J. et al. Validation of the MOS SF-36 for quality of life assessment of patients with systemic lupus erythematosus patients in Singapore. J. Rheumatol. 26, 97–102 (1999).
Thumboo, J. et al. Validation of the Chinese SF-36 for quality of life assessment in patients with systemic lupus erythematosus. Lupus 9, 708–712 (2000).
Thumboo, J. et al. A prospective study of factors affecting quality of life in systemic lupus erythematosus. J. Rheumatol. 27, 1414–1420 (2000).
Wang, C., Mayo N. E. & Fortin, P. R. The relationship between health related quality of life and disease activity and damage in systemic lupus erythematosus. J. Rheumatol. 28, 525–532 (2001).
Strand, V. et al. Baseline data from 5 randomized controlled trials (RCTs) demonstrate that systemic lupus erythematosus (SLE) impacts all domains of health related quality of life (HRQoL). Arthritis Rheum. 54, S277 (2006).
Panopalis, P. et al. The systemic lupus erythematosus Tri-Nation Study: longitudinal changes in physical and mental well-being. Rheumatology (Oxford) 44, 751–755 (2005).
Ware, J. E. Jr & Sherbourne, C. D. The MOS 36-item short form health survey (SF-36). Conceptual framework and item selection. Med. Care 30, 473–483 (1992).
Jolly, M. How does quality of life of patients with systemic lupus erythematosus compare with that of other common chronic illness? J. Rheumatol. 32, 1706–1708 (2005).
Panopalis, P. & Clarke, A. E. Quality of life in systemic lupus erythematosus. Clin. Dev. Immunol. 13, 321–324 (2006).
McElhone, K., Abbott, J. & The, L. S. A review of health related quality of life in systemic lupus erythematosus. Lupus 15, 633–643 (2006).
Bultink, I. E., Turkstra, F., Dijkmans, B. A. & Voskuyl, A. E. High prevalence of unemployment in patients with systemic lupus erythematosus: association with organ damage and health-related quality of life. J. Rheumatol. 35, 1053–1057 (2008).
Vu, T. V. & Escalante, A. A comparison of the quality of life of patients with systemic lupus erythematosus with and without endstage renal disease. J. Rheumatol. 26, 2595–2601 (1999).
Boehncke, W. H., Ochsendorf, F., Paeslack, I., Kaufmann, R. & Zollner, T. M. Decorative cosmetics improve the quality of life in patients with disfiguring skin diseases. Eur. J. Dermatol. 12, 577–580 (2002).
Fortin, P. R. et al. Impact of disease activity and cumulative damage on the health of lupus patients. Lupus 7, 101–107 (1998).
Tse, K. C., Tang, C. S., Lio, W. I., Lam, M. F. & Chan, T. M. Quality of life comparison between corticosteroid-and-mycophenolate mofetil and corticosteroid-and-oral cyclophosphamide in the treatment of severe lupus nephritis. Lupus 15, 371–379 (2006).
Mok, C. C., Ho, L. Y., Cheung, M. Y., Yu, K. L. & To, C. H. Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2-year prospective study. Scand. J. Rheumatol. 5, 1–7 (2008).
Leong, K. P. et al. Development and preliminary validation of a systemic lupus erythematosus-specific quality-of-life instrument (SLEQOL). Rheumatology (Oxford) 44, 1267–1276 (2005).
McElhone, K. et al. Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus. Arthritis Rheum. 57, 972–979 (2007).
Dorward, L. C. et al. The development of the L-QoL: a quality-of-life instrument specific to systemic lupus erythematosus. Ann. Rheum. Dis. 68, 196–200 (2009).
Thumboo, J. & Wee, H. L. Systemic lupus erythematosus in Asia: is it more common and more severe? J. Rheumatol. 9, 320–326 (2006).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary information
Terms used in evaluating the socioeconomic costs of SLE (DOC 31 kb)
Rights and permissions
About this article
Cite this article
Lau, C., Mak, A. The socioeconomic burden of SLE. Nat Rev Rheumatol 5, 400–404 (2009). https://doi.org/10.1038/nrrheum.2009.106
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2009.106
This article is cited by
-
Prevalence and biopsychosocial factors associated with depressive symptoms among patients living with systemic lupus erythematosus in clinical settings in urban Thailand
BMC Psychiatry (2022)
-
A 5-Year Retrospective, Observational Study Assessing Rheumatoid Arthritis Disease Outcome Measures to Characterize Systemic Lupus Erythematosus Burden in the USA
Rheumatology and Therapy (2022)
-
Transcriptomic analysis of immune cells in a multi-ethnic cohort of systemic lupus erythematosus patients identifies ethnicity- and disease-specific expression signatures
Communications Biology (2021)
-
Global epidemiology of systemic lupus erythematosus
Nature Reviews Rheumatology (2021)
-
Pharmacokinetics and Safety of Intravenous and Subcutaneous Auto-injector Single-dose Belimumab in Healthy Chinese Volunteers: A phase 1, Randomized, Open-label Study
Rheumatology and Therapy (2021)